BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20401461)

  • 21. Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial.
    Gealekman O; Guseva N; Gurav K; Gusev A; Hartigan C; Thompson M; Malkani S; Corvera S
    Diabetologia; 2012 Oct; 55(10):2794-2799. PubMed ID: 22847059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
    Kim H; Haluzik M; Gavrilova O; Yakar S; Portas J; Sun H; Pajvani UB; Scherer PE; LeRoith D
    Diabetologia; 2004 Dec; 47(12):2215-25. PubMed ID: 15662559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells.
    Kim HS; Hwang YC; Koo SH; Park KS; Lee MS; Kim KW; Lee MK
    PLoS One; 2013; 8(1):e50128. PubMed ID: 23372643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
    Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
    Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue.
    Kim JJ; Li P; Huntley J; Chang JP; Arden KC; Olefsky JM
    Diabetes; 2009 Jun; 58(6):1275-82. PubMed ID: 19289458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet.
    Kuda O; Jelenik T; Jilkova Z; Flachs P; Rossmeisl M; Hensler M; Kazdova L; Ogston N; Baranowski M; Gorski J; Janovska P; Kus V; Polak J; Mohamed-Ali V; Burcelin R; Cinti S; Bryhn M; Kopecky J
    Diabetologia; 2009 May; 52(5):941-51. PubMed ID: 19277604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
    Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
    Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
    Churi SB; Abdel-Aleem OS; Tumber KK; Scuderi-Porter H; Taylor BK
    J Pain; 2008 Jul; 9(7):639-49. PubMed ID: 18387855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial Cell-Targeted Deletion of PPAR
    Akiyama TE; Skelhorne-Gross GE; Lightbody ED; Rubino RE; Shi JY; McNamara LA; Sharma N; Zycband EI; Gonzalez FJ; Liu H; Woods JW; Chang CH; Berger JP; Nicol CJB
    J Pharmacol Exp Ther; 2019 Mar; 368(3):514-523. PubMed ID: 30606762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone promotes PPARγ-dependent and -independent alterations in gene expression in mouse islets.
    Welters HJ; El Ouaamari A; Kawamori D; Meyer J; Hu J; Smith DM; Kulkarni RN
    Endocrinology; 2012 Oct; 153(10):4593-9. PubMed ID: 22807489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.
    Askari B; Kanter JE; Sherrid AM; Golej DL; Bender AT; Liu J; Hsueh WA; Beavo JA; Coleman RA; Bornfeldt KE
    Diabetes; 2007 Apr; 56(4):1143-52. PubMed ID: 17259370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome.
    Wang S; Goodspeed L; Turk KE; Houston B; den Hartigh LJ
    Endocrinology; 2017 Sep; 158(9):2848-2859. PubMed ID: 28651330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.
    Berthiaume M; Sell H; Lalonde J; Gélinas Y; Tchernof A; Richard D; Deshaies Y
    Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1116-23. PubMed ID: 15256367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice.
    Harmon GS; Dumlao DS; Ng DT; Barrett KE; Dennis EA; Dong H; Glass CK
    Nat Med; 2010 Mar; 16(3):313-8. PubMed ID: 20154695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.
    Hansmann G; Wagner RA; Schellong S; Perez VA; Urashima T; Wang L; Sheikh AY; Suen RS; Stewart DJ; Rabinovitch M
    Circulation; 2007 Mar; 115(10):1275-84. PubMed ID: 17339547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice.
    Stromsdorfer KL; Yamaguchi S; Yoon MJ; Moseley AC; Franczyk MP; Kelly SC; Qi N; Imai S; Yoshino J
    Cell Rep; 2016 Aug; 16(7):1851-60. PubMed ID: 27498863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality.
    Minge CE; Bennett BD; Norman RJ; Robker RL
    Endocrinology; 2008 May; 149(5):2646-56. PubMed ID: 18276752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.